DDrare: Database of Drug Development for Rare Diseases

Searched query = "Sturge-Weber syndrome", "Síndrome de Sturge-Weber"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Cannabidiol; Crema de rapamicina al 1% y excipientes; Crema placebo (excipiente); Topical Rapamycin; Everolimus; Modified Atkins diet; Preservative free artificial tear gel.; Rapamicina tópica al 1% y excipiente; Rapamycin; Sirolimus; Timolol

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01997255 (ClinicalTrials.gov)	April 2014	15/11/2013	Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)	An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome	Sturge Weber Syndrome	Drug: Everolimus	Baylor College of Medicine	Novartis Pharmaceuticals	Withdrawn	2 Years	18 Years	Both	0	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01997255
(ClinicalTrials.gov)

April 2014

15/11/2013

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome

Sturge Weber Syndrome

Drug: Everolimus

Baylor College of Medicine

Novartis Pharmaceuticals

Withdrawn

2 Years

18 Years

Both

Phase 2

United States